EUVIMEDOdkrijte EUVIMED
CrossrefInformačná karta

Living Liver Donors With Obesity and Metabolic Risk: Review and Guidance on Donor Triage and Care

Hyosun Han, Kristina Rachel Chacko, Babak. Orandi, Dagny E. von Ahrens, Alexandra Shingina, Susan C. Kim, Kymberly D. Watt, AnnMarie Liapakis

Clinical Transplantation · 2026-11 · 40 (11)

DOI: 10.1111/ctr.70681 ↗
AbstraktBibliografické údaje

Abstrakt

ABSTRACT With the increasing prevalence of obesity in the United States, potential living liver donors (LLDs) are similarly impacted. Historically, LLDs with obesity are deemed too high risk for donation due to concern for hepatic steatosis (HS) or post‐surgical complications. Evolving data show that obesity is not the absolute indicator of HS and metabolic risk. Instead, distribution of fat in the visceral area as well as body composition drive the risk for metabolic dysfunction associated steatotic liver disease (MASLD). Prior practice patterns of denial of obese LLDs with metabolic risk require a change in mindset from the liver transplant community with a thoughtful, individualized risk assessment of all LLDs. By losing weight utilizing various dietary and procedural strategies, these “gray zone” LLDs improve their metabolic risk profile and can move into a low risk “green zone”, thus expanding the donor pool. Little data exist whether “gray zone” LLDs who succeed in weight loss have long‐term consequences to their own health if they regain their weight or the clinical impact on their LDLT recipients. Ethical and financial questions remain as to the LDLT centers’ direct responsibility to maintaining donor health. Future studies evaluating interventions and outcomes are needed.

Vedomosti, ktoré zodpovedajú vašej práci.

Od bezplatného začiatku cez osobnú rešerš literatúry až po kompletný Research Suite.

Zobraziť tarify →

Sú zahrnuté všetky plné texty vydavateľov?

Nie. Bibliografické záznamy, abstrakty a plné texty sú odlišné typy obsahu. To, či je plný text dostupný, závisí od zdroja, Open Access a vašich existujúcich licencií. Tarif EUVIMED nenahrádza dodatočné práva vydavateľa.

Zobraziť tarify →